Prana’s Parkinson’s drug meets foundation’s toxicology, genotoxicity and safety milestones
Share This Story
Prana Biotechnology Limited (NASDAQ: PRAN) announced today that its lead compound in development for Parkinson's disease (PD), PBT434, had progressed successfully though a series of preclinical development studies used to assess the suitability of a candidate compound for human clinical studies. The studies were funded by The Michael J. Fox Foundation (MJFF) 2011 Pipeline Program to support its 'Therapeutic Development Initiative.' The MJFF Program grant is milestone based. PBT434 achieved all of its milestones in preclinical toxicology studies, genotoxicity and safety pharmacology -- allowing the compound to be positioned for larger scale animal toxicology studies prior to commencing clinical trials.
more: http://medcitynews.com/2012/08/pranas-parkinsons-drug-meets-fox-foundations-preclinical-toxicology-genotoxicity-and-safety-milestones/#ixzz2zLw7ssi3
I was suffering from Parkinson's since 5 years & life had become disastrous for me.75 % of my body was covered by Tremors.After taking herb at multivitamincare.org under supervision of their doctor, i started getting results within three to four weeks of the remedy .Treatment went very well and tremors are gone. I’m a strong advocate for other PD disease patients seeking help , multivitamin herbal remedies it the right process, “What they’ve done for me and my life, it’s been almost a miracle.”
ReplyDelete